NCT03859050 Alveolar Macrophage Programming Following Endotoxin Exposure
| NCT ID | NCT03859050 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Jewish Health |
| Condition | ARDS, Human |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2019-03-18 |
| Primary Completion | 2029-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2019-03-18 with a primary completion date of 2029-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).
Eligibility Criteria
Inclusion Criteria: 1. Written, informed consent 2. Age 18-50 Exclusion Criteria: 1. Current or recent illness (past 2 weeks) 2. Presence or prior history of cardiac, pulmonary or systemic disease 3. Bleeding disorder, use of systemic anticoagulants or antiplatelet therapy 4. American Society of Anesthesiology (ASA) class 2 or greater 5. Immunocompromised state (HIV, immunoglobulin deficiency, systemic immunosuppressants) 6. Use of any inhaled substance, including tobacco, marijuana, e-cigarrettes, cocaine, methamphetamines, or toxic vapors in the past 3 months or greater than 10 pack-year smoking history 7. Alcohol use disorder or greater than 7 drinks/week for women or greater than 14 drinks/week for men in the past 3 months 8. Allergy or prior adverse reaction to lidocaine, midazolam or fentanyl 9. Abnormal spirometry or electrocardiogram at time of screening 10. Pregnant (based on urine pregnancy test) or breast feeding
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03859050 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying ARDS, Human. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03859050 currently recruiting?
Yes, NCT03859050 is actively recruiting participants. Contact the research team at mouldk@njhealth.org for enrollment information.
Where is the NCT03859050 trial being conducted?
This trial is being conducted at Denver, United States.
Who is sponsoring the NCT03859050 clinical trial?
NCT03859050 is sponsored by National Jewish Health. The trial plans to enroll 25 participants.